×

BioCryst to Announce 2014 Financial Results February 18 & Present at the 2015 Leerink Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 5, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that its fourth quarter 2014 financial results will be released on Wednesday, February 18, 2015. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab, II, Senior Vice President & Chief Financial Officer, Dr. William P. Sheridan, Senior Vice President & Chief Medical Officer and Lynne Powell, Senior Vice President & Chief Commercial Officer.

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm. To participate in the conference call, please dial 1-877-303-8027 (United States) or 1-760-536-5165 (International). No passcode is needed for the call.

Executives from BioCryst are also scheduled to present and provide an update regarding the Company's development programs at the 2015 Leerink Global Healthcare conference in New York on Thursday, February 12, 2015 at 8:55 a.m. Eastern Time.

Links to a live audio webcast and replay of the Leerink presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, including BCX4161, BCX7353 and other second generation compounds, and BCX4430, a broad spectrum viral RNA polymerase inhibitor. For more information, please visit the Company's website at www.BioCryst.com. In December 2014, RAPIVABTM (peramivir injection), a viral neuraminidase inhibitor, was approved by the FDA. For more information regarding RAPIVAB, please visit http://rapivab.com/.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at http://investor.shareholder.com/biocryst/sec.cfm.

BCRXW

CONTACT: Robert Bennett BioCryst Pharmaceuticals +1-919-859-7910

Source:BioCryst Pharmaceuticals